---
granola_id: 9f0e6b83-6eb3-4f05-8b0f-e4511ecd4d7e
title: "Sadiqa Mahmood and Virtue"
type: note
created: 2025-07-25T17:58:32.547Z
updated: 2025-09-30T14:11:39.560Z
attendees:
  - sm@prudentiasciences.com
  - sd@virtuevc.com
---
### Hiring Updates

- Made offer to CTO with 2 backup candidates
	- Coming from cybersecurity startup backed/incubated by Madera
	- Previously at Microsoft, Salesforce, Hitachi plus two other startups
- Key learnings from hiring process:
	- Good talent wants to build consumer apps, avoiding enterprise tech
	- Lot of mediocre talent in market
	- Some good candidates wouldn’t fit customer conversations
- Made offer to Head of AI/Applied ML
	- Coming from Google, Apple, and was head of AI at Grammarly
	- Math major at Princeton, PhD at Hopkins (4th year dropout)
	- Focus on candidates who drove ML for product core at ad/search businesses
	- Will help build foundational models for Series A narrative
- Ben Klein hired for partnerships, hit the ground running
- Total team will reach 11 people maximum

### Series A Fundraising Strategy

- Targeting $20-25M raise starting after Labor Day
- Insights and Sequoia both back in process
	- Doug at Insights bringing life sciences and enterprise tech teams
	- Dylan from life sciences team understands the space well
- Three potential narratives for raise:
	- Pulse for biotechs - lightweight click-through version to capture sell-side market
	- GV China expansion - mapping entire China market plus US market expansion
	- Foundational models - competitive landscape module with assessment framework
		- Scraping data, new platform module
		- Shinogi and Mereda signed as design partners
- Financial institutions interest:
	- Allybridge wants 5 seats (VC license model)
	- Approaching JPMorgan Chase, LinkedIn life sciences, Remington
	- Citadel and Two Sigma approached about data licensing

### Commercial Progress

- Product-market fit landed well since March finalization
- Use case evolution beyond original diligence/valuation:
	- Roche testing platform to stage shelved assets for sale
	- Supported biotech Series A with three-asset pipeline staging
- Two customer types identified:
	- Biotech - always use platform to stage/present assets
	- Pharma - both inbound and outbound deals
- CSL first all-TA contract in progress:
	- Budget approved, implementation end of year
	- 5 total TAs, working through CBO and SVP of Corp Dev
- Revenue pipeline:
	- $2M/year Roche contract pending (2-year, $4M total) - 4 months in negotiation
	- $5M total in redline contracts
	- $3.7M additional pipeline in budget negotiations
- Customers describing platform as “operating system for deal making”
	- Similar to how clinical ops uses Veeva for workflow

### Strategic Insights and Positioning

- Platform identified KRAS validation in animal studies for status epilepticus asset
	- Changed valuation dynamic from small epilepsy market to huge KRAS opportunity
	- Minimum $1.2B valuation potential, maximum $3.3B
- Competitive landscape analysis:
	- Harvey comparison - “Harvey for life sciences” workflow support
	- Sleuth focuses on deal activity prediction vs. deep clinical comparison
	- Standard Model fine-tuning vision language models for pharma
- Need partnerships with NVIDIA, AWS, or OpenAI for foundational model story
- Announcing something soon - will circulate to key stakeholders

Chat with meeting transcript: https://notes.granola.ai/d/9f0e6b83-6eb3-4f05-8b0f-e4511ecd4d7e
